To understand why boldenone undecylenate behaves differently than testosterone, you need to get down to the molecular and cellular level. The editors traced the path of the substance from the cleavage of the ester to the nucleus of the muscle cell and analyzed which links of this path are confirmed by research, and which remain assumptions.
From prodrugs to active hormone
Boldenone undecylenate itself does not interact with receptors: it is a prodrug. The bulky undecylenate ester does not allow the molecule to "sit down" properly in the binding pocket of the androgen receptor. First, the ester must be cleaved by esterase enzymes, which are present in the blood and tissues.
The speed of this process is determined not so much by the activity of esterases, but by how slowly the lipophilic molecule leaves the oil depot in the muscle. Therefore, the mechanism of action of the drug is always "stretched in time": at each moment, only that part of boldenone that managed to be released and freed from the ester works.
Free boldenone in the blood, like testosterone, partially binds to transport proteins — sex hormone-binding globulin (SHBG) and albumin. The free and weakly bound fraction with albumin is considered biologically available. There is limited data on the affinity of boldenone for SHBG in humans.
Next, the free steroid easily passes through the cell membrane due to its fat solubility. Special "transporters" are not needed for this - that is why androgens affect almost all tissues where there are appropriate receptors: muscles, bones, skin, hematopoietic bone marrow, brain and liver.
Androgen receptor: how binding occurs
Androgen receptor (AR) is an intracellular protein from the family of nuclear receptors. In an inactive state, it is in the cytoplasm in a complex with heat shock proteins. When androgen enters the binding pocket, the receptor changes conformation, is freed from chaperone proteins and forms a dimer.
The dimer moves to the nucleus, where it binds to specific areas of DNA — androgen response elements. Together with coactivator proteins, it changes the rate of transcription of target genes. This classical "genomic" pathway is described in detail in reviews of the pharmacology of AAS, in particular in the work of Kicman (2008).
- Release from depot and splitting of ester.
- Penetration of free boldenone into the cell.
- Binding to the androgen receptor and changing its conformation.
- Dimerization and translocation to the nucleus.
- Activation of genes and synthesis of new proteins.
In addition to the genomic pathway, rapid "non-genomic" effects through membrane signaling cascades have been described for androgens. Their role for anabolic action is generally less well studied, and there are practically no specific studies on boldenone, so the editors do not make any quantitative conclusions here.
It is important that the androgen receptor is the same in different tissues. The "anabolicity" or "androgenicity" of a particular substance does not depend on individual receptors, but on how the molecule is metabolized in the tissues and how active its metabolites are.
Protein synthesis and muscle fiber growth
In skeletal muscles, the activation of androgen receptors enhances the synthesis of contractile proteins and contributes to a positive nitrogen balance. For testosterone, this has been demonstrated in controlled studies, particularly in the work of the Bhasin group, where supraphysiological doses increased lean mass and muscle cross-sectional area.
Another important mechanism is the activation of satellite cells, muscle stem cells. They divide and merge with existing fibers, adding new nuclei. This allows the fiber to grow further, because each nucleus "serves" a limited volume of cytoplasm. Studies of biopsies have shown an increase in the number of myonuclei with the use of testosterone.
An anti-catabolic effect is also discussed: androgens may compete with glucocorticoids for influencing the expression of protein degradation genes. This mechanism is described in reviews mainly as a hypothesis based on experimental data and does not have precise quantitative estimates for humans.
For boldenone itself, experimental data on hypertrophy were obtained mainly on animals — in veterinary and toxicological studies. They do not allow direct transfer to humans: doses, species, housing conditions and evaluation methods differ. That is why we describe the mechanism through the general patterns of androgens.
It should also be remembered that androgenic stimulation is not limited to the muscles. The same mechanism enhances the production of erythropoietin in the kidneys, and erythropoiesis in the bone marrow; in the skin - the work of the sebaceous glands. Anabolic and "side" effects have a common molecular root.
The role of the C1–C2 double bond
An additional double bond in ring A is the main structural difference between boldenone and testosterone. It changes the shape of the ring and affects how the molecule is "recognized" by metabolic enzymes. The same changes combined with other modifications are used in metandienone, so the Δ1-steroid class is well known to pharmacologists.
| Enzyme | Effect on testosterone | Effect on boldenone |
|---|---|---|
| Aromatase | Converts to estradiol | Also converts to estradiol; according to reviews - slower |
| 5α-reductase | Forms DHT, a stronger androgen | Forms dihydroboldenone (1-testosterone), an active androgen |
| 17β-hydroxysteroid dehydrogenase | Oxidizes to androstenedione | Oxidizes to androstadienedione |
Interestingly, the aromatization of boldenone gives the same estradiol as the aromatization of testosterone: ring A still becomes aromatic during this reaction, and the difference in the double bond "disappears". Therefore, the estrogenic effects of boldenone are those of normal estradiol.
In tissues with high activity of 5α-reductase, testosterone is "amplified", turning into DHT. Boldenone is converted to dihydroboldenone, which is also an active androgen. Therefore, the popular thesis that boldenone "does not produce" androgenic effects in the skin or prostate has no convincing basis.
Finally, the double bond affects the excretion routes: the main urinary metabolites of boldenone are different from those of testosterone, which allows anti-doping laboratories to specifically detect it. Read more about this in the material on pharmacokinetics.
What remains unknown
Despite decades of veterinary use, much of the mechanistic data on boldenone has been derived from animals or extrapolated from studies of other androgens. For humans, there are no controlled data on the dose dependence of the effects, on the exact affinity to the receptor in tissues and on the ratio of anabolic and androgenic effects.
Classical "anabolic indices", which are often cited in popular tables, were obtained in experiments on castrated rats by measuring the mass of m. levator ani and prostate. Modern pharmacology considers this method to be very inaccurate for predicting effects in humans, as the reviews of Kicman and other authors directly write about.
It is also unknown how the effects of boldenone change with the simultaneous use of other substances, which is a typical situation outside of medicine. Studies of AAS users, such as the Dutch prospective study HAARLEM, capture the effects of "real" regimens in general, without being able to isolate the contribution of a single substance.
Therefore, any categorical statements about the "unique" mechanism of boldenone should be taken critically. At the level of molecular biology, it behaves like a typical androgen with some metabolic features.
Editorial conclusions
The mechanism of action of boldenone undecylenate is classic for androgens: after cleavage of the ester, boldenone activates the androgen receptor, triggers gene transcription, and enhances muscle protein synthesis and satellite cell activation.
The C1–C2 double bond alters metabolism, but does not abolish either aromatization to estradiol or formation of active 5α-reduced androgen. So anabolic and side effects have a common source.
Much of the popular notion of boldenone's "special" mechanism is based on animal data and outdated indices rather than human studies.
Our articles on the estrogenic and progestogenic activity of boldenone, on its effect on the own production of testosterone and on the tests controlled by the doctor will help to continue the topic.
References
- Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502–521.
- Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med. 1996;335(1):1–7.
- Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172–E1181.
- Schänzer W. Metabolism of anabolic androgenic steroids. Clin Chem. 1996;42(7):1001–1020.
- Smit DL, Buijs MM, de Hon O, den Heijer M, de Ronde W. Positive and negative side effects of androgen abuse. The HAARLEM study: a one-year prospective cohort study in 52 amateur athletes. Scand J Med Sci Sports. 2021;31(2):427–438.
- Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34(8):513–554.
